Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pacific Biosciences (DE:P09)
BERLIN:P09
RESEARCH TOOLSreports
Holding DE:P09?
Track your performance easily
See the Price Targets and Ratings of:
P09 Analyst Ratings
Moderate Buy
3 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
P09 Stock 12 Month Forecast
Average Price Target
€2.94
▲(63.17% Upside)
| Highest Price Target€5.74 | Average Price Target€2.94 | Lowest Price Target€1.91 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Piper Sandler
Reiterated
11/11/24
Scotiabank
Reiterated
11/11/24
Morgan Stanley
Reiterated
11/11/24
TD Cowen
Assigned
11/08/24
Barclays
Reiterated
11/08/24
Canaccord Genuity
Reiterated
11/07/24
Stephens
Reiterated
08/13/24
Cantor Fitzgerald
Reiterated
08/08/24
Jefferies
Initiated
06/03/24
Goldman Sachs
€2.39
Hold
32.87%
Upside
Reiterated
05/10/24
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NASDAQ: NTLA), Liquidia Technologies (NASDAQ: LQDA) and Pacific Biosciences (NASDAQ: PACB)
J.P. Morgan
―
Hold
―
Downgraded
04/21/24
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (NASDAQ: CYTH), CytomX Therapeutics (NASDAQ: CTMX) and Pacific Biosciences (NASDAQ: PACB)
Bernstein
€8.61→€2.39
Buy
32.87%
Upside
Reiterated
04/18/24
PacBio price target lowered to $2.50 from $9 at BernsteinPacBio price target lowered to $2.50 from $9 at Bernstein
Nephron
€1.91
Hold
6.30%
Upside
Downgraded
04/16/24
Nephron downgrades Pacific Biosciences of California (PACB) to HoldNephron analyst Jack Meehan downgraded Pacific Biosciences of California (NASDAQ: PACB) from Buy to Hold with a price target of $2.00.
Wolfe Research
―
Hold
―
Initiated
12/12/23
PacBio initiated with neutral view at Wolfe ResearchPacBio initiated with neutral view at Wolfe Research
Best Analysts Covering Pacific Biosciences
Which Analyst Should I Follow If I Want to Buy DE:P09 and Sell After:
1 Month
xxx
Success Rate
9/18 ratings generated profit
Average Return
+3.88%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.88% per trade.
3 Months
xxx
Success Rate
5/9 ratings generated profit
Average Return
-5.30%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of -5.30% per trade.
1 Year
Success Rate
7/18 ratings generated profit
Average Return
+14.41%
reiterated a buy rating 20 days ago
Copying Kyle Mikson CFA's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of +14.41% per trade.
2 Years
xxx
Success Rate
2/9 ratings generated profit
Average Return
-40.33%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 22.22% of your transactions generating a profit, with an average return of -40.33% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
P09 Analyst Recommendation Trends
Rating
May 24
Jun 24
Aug 24
Oct 24
Nov 24
Strong Buy
8
8
7
5
6
Buy
0
0
1
1
2
Hold
8
9
9
6
9
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
16
17
17
12
17
Each month's total comprises the sum of three months' worth of ratings.
P09 Financial Forecast
P09 Stock Forecast FAQ
What is DE:P09’s average 12-month price target, according to analysts?
Based on analyst ratings, Pacific Biosciences’s 12-month average price target is €2.94.
What is DE:P09’s upside potential, based on the analysts’ average price target?
Pacific Biosciences has 63.17% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Pacific Biosciences a Buy, Sell or Hold?
Pacific Biosciences has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 4 hold ratings and 0 sell ratings.
What is Pacific Biosciences’s share price target?
The average share price target for Pacific Biosciences is €2.94. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €5.74 ,and the lowest forecast is €1.91. The average share price target represents 63.17% Increase from the current price of €1.8.
The highest analyst share price target is €5.74 ,and the lowest forecast is €1.91. The average share price target represents 63.17% Increase from the current price of €1.8.
What do analysts say about Pacific Biosciences?
Pacific Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of Pacific Biosciences?
To buy shares of DE:P09, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.